CHROMADERM is developing a first-in-class treatment for melasma and other skin hyperpigmentation disorders. The team will in-license and re-purpose Ruboxistaurin, a potent and selective protein kinase C-beta (“PKCβ”) inhibitor from Eli Lilly. Unlike the existing skin-lightening agents, Ruboxistaurin presents a potentially safer and more efficacious approach.